Skip to main content

Table 1 Characteristics of eligible studies in the qualitative and quantitative synthesis

From: Clinicopathological and prognostic significance of nestin expression in patients with breast cancer: a systematic review and meta-analysis

Study

Year

Country

Cancer types

Cases/controls

Age (years)

Follow-up time

Method

Cut-off value (positive/high)

Survival outcomes

Source of data

NOS score

Asleh et al. [21]

2018

Canada

IBC

339/2895

NR

12.6 years (median)

IHC

A2 > 0

BCSS(U), BCSS(M)

Direct

8

Asleh et al. [52]

2019

Denmark

MBC

29/216

NR

NR

IHC

A2 > 0

OS(U), OS(M)

PFS(U), PFS(M)

Direct

8

De Lara et al. [22]

2019

Sweden

MBC

25/110

NR

10 years

IHC

A2 > 0

OS(U), DMFS(U)

OS(M), DMFS(M)

Curve

Direct

8

Gao et al. [23]

2014

China

BC

42/109

32–79

NR

IHC

A1 > 0

BCSS(U)

Curve

8

Krüger et al. [24]

2017

Norway

IBC

I: 50/47

II: 35/244

III: 51/130

IV: 44/143

I: 50–69

II: 50–69

III, IV: NR

I: 13 years (median)

II, III, IV: NR

IHC

At least 3 clearly positive cells

I: BCSS(U), BCSS(M)

II, III, IV: NR

Direct

8

Liu et al. [26]

2010

China

DCIS, IDC

24/126

27–80

NR

IHC

A5 > 0

BCSS(U)

Curve

8

Liu et al. [25]

2012

China

DCIS, IDC

62/241

NR

7.5 years

IHC

A5 > 0

BCSS(U)

Curve

7

Meisen et al. [54]

2014

USA

BC

83/83

NR

NR

qRT-PCR

Median

DMFS(U)

Curve

7

Nowak et al. [50]

2017

Poland

IDC

109 (total)

NR

NR

IHC

Nestin+ MVD

> 75.76 (median)

OS(U), OS(M), RFS(U)

Direct curve

7

Nowak et al. [51]

2018

Poland

IDC

39/83

NR

1–80 months

IHC

A3*B1 > 0

OS(U)

Curve

7

Parry et al. [27]

2008

UK

IBC

20/223

NR

5.2–135.3 months

IHC

A5 > 0

BCSS(U)

Curve

8

Piras et al. [28]

2011

Italy

BC

28/25

32–67

82–194 months

IHC

A6 > 0

OS(U)

Curve

8

Tampaki et al. [55]

2017

Greece

BC

26/115

NR

NR

IHC

A4 > 0

RFS(U), RFS(M)

Curve direct

7

Zhao et al. [20]

2014

China

TNBC

41/109

NR

NR

IHC

A1 > 0

OS(U)

Curve

7

Zhu et al. [56]

2009

China

DCIS, IDC

20/100

NR

NR

IHC

A5 > 0

NR

NR

–

  1. IBC invasive breast cancer, MBC metastatic breast cancer, BC breast cancer, DCIS ductal carcinoma in situ, IDC invasive ductal carcinoma, TNBC triple-negative breast cancer, BCSS breast cancer-specific survival, OS overall survival, PFS progression-free survival, DMFS distant metastasis-free survival, RFS recurrence-free survival, NR not reported, U univariate analysis, M multivariate analysis
  2. A: percentage of positive cells. A1: scored 0 (< 1%), 1 (1–9%), 2 (≥ 10%); A2: scored 0 (< 1%), 1 (≥ 1%); A3: scored 0 (0%), 1 (< 10%), 2 (10–50%), 3 (51–80%), 4 (> 80%); A4: scored 0 (≤ 5%), 1 (> 5%); A5: scored 0 (< 1%), 1 (1–9%), 2 (≥ 10%); A6: scored 0 (< 10%), 1 (≥ 10%)
  3. B: intensity of staining. B1: scored 0 (absence of staining), 1 (weak staining), 2 (moderate staining), 3 (strong staining)